The impact of FGFR1 and FRS2α expression on sorafenib treatment in metastatic renal cell carcinoma

BMC Cancer

Volumn 15, Issue 1, 2015, Pages

  Ho, Thai H ^a   Liu, Xian De ^b   Huang, Yanqing ^c   Warneke, Carla L ^b   Johnson, Marcella M ^b   Hoang, Anh ^b   Tamboli, Pheroze ^b   Wang, Fen ^c   Jonasch, Eric ^b  

^a MAYO CLINIC   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c TEXAS A AND M HEALTH SCIENCE CENTER   (United States)

Author keywords

FGF; Renal cell carcinoma; Sorafenib; VEGF

Indexed keywords

ALPHA INTERFERON; FIBROBLAST GROWTH FACTOR RECEPTOR 1; FIBROBLAST GROWTH FACTOR RECEPTOR 2; FIBROBLAST GROWTH FACTOR RECEPTOR SUBSTRATE 2 ALPHA; SORAFENIB; UNCLASSIFIED DRUG; VASCULOTROPIN; ANTINEOPLASTIC AGENT; CARBANILAMIDE DERIVATIVE; FGFR1 PROTEIN, HUMAN; FRS2 PROTEIN, HUMAN; MEMBRANE PROTEIN; NICOTINAMIDE; SIGNAL TRANSDUCING ADAPTOR PROTEIN;

ADULT; AGED; ANEMIA; ARTICLE; CANCER GROWTH; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME INHIBITION; FEMALE; HUMAN; IMMUNOFLUORESCENCE; IN SITU HYBRIDIZATION; KIDNEY METASTASIS; MALE; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; RISK FACTOR; TUMOR RESISTANCE; ANALOGS AND DERIVATIVES; BIOSYNTHESIS; CARCINOMA, RENAL CELL; CLINICAL TRIAL; GENE EXPRESSION REGULATION; METABOLISM; MIDDLE AGED; PHASE 2 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; VERY ELDERLY;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MEMBRANE PROTEINS; MIDDLE AGED; NIACINAMIDE; PHENYLUREA COMPOUNDS; PROSPECTIVE STUDIES; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 1; TREATMENT OUTCOME;

EID: 84928265803     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/s12885-015-1302-1     Document Type: Article

References (25)

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015;65(1):5-29.
2. Atkins MB, Bukowski RM, Escudier BJ, Figlin RA, Hudes GH, Kaelin Jr WG, et al. Innovations and challenges in renal cancer: summary statement from the Third Cambridge Conference. Cancer. 2009;115(10 Suppl):2247-51.
3. Bhide RS, Lombardo LJ, Hunt JT, Cai ZW, Barrish JC, Galbraith S, et al. The antiangiogenic activity in xenograft models of brivanib, a dual inhibitor of vascular endothelial growth factor receptor-2 and fibroblast growth factor receptor-1 kinases. Mol Cancer Ther. 2010;9(2):369-78.
4. Allen E, Walters IB, Hanahan D. Brivanib, a dual FGF/VEGF inhibitor, is active both first and second line against mouse pancreatic neuroendocrine tumors developing adaptive/evasive resistance to VEGF inhibition. Clin Cancer Res. 2011;17(16):5299-310.
5. Casanovas O, Hicklin DJ, Bergers G, Hanahan D. Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell. 2005;8(4):299-309.
6. Welti JC, Gourlaouen M, Powles T, Kudahetti SC, Wilson P, Berney DM, et al. Fibroblast growth factor 2 regulates endothelial cell sensitivity to sunitinib. Oncogene. 2010;30(10):1183-93.
7. Sharpe K, Stewart GD, Mackay A, Van Neste C, Rofe C, Berney D, et al. The effect of VEGF-targeted therapy on biomarker expression in sequential tissue from patients with metastatic clear cell renal cancer. Clin Cancer Res. 2013;19(24):6924-34.
8. Dempke WC, Zippel R. Brivanib, a novel dual VEGF-R2/bFGF-R inhibitor. Anticancer Res. 2010;30(11):4477-83.
9. Sato T, Gotoh N. The FRS2 family of docking/scaffolding adaptor proteins as therapeutic targets of cancer treatment. Expert Opin Ther Targets. 2009;13(6):689-700.
10. Busch J, Seidel C, Weikert S, Wolff I, Kempkensteffen C, Weinkauf L, et al. Intrinsic resistance to tyrosine kinase inhibitors is associated with poor clinical outcome in metastatic renal cell carcinoma. BMC Cancer. 2011;11:295.
11. Tsimafeyeu I, Demidov L, Stepanova E, Wynn N, Ta H. Overexpression of fibroblast growth factor receptors FGFR1 and FGFR2 in renal cell carcinoma. Scand J Urol Nephrol. 2011;45(3):190-5.
12. Ahmad T, Eisen T. Kinase inhibition with BAY 43-9006 in renal cell carcinoma. Clin Cancer Res. 2004;10(18 Pt 2):6388S-92.
13. Jonasch E, Corn P, Pagliaro LC, Warneke CL, Johnson MM, Tamboli P, et al. Upfront, randomized, phase 2 trial of sorafenib versus sorafenib and low-dose interferon alfa in patients with advanced renal cell carcinoma: clinical and biomarker analysis. Cancer. 2010;116(1):57-65.
14. Pocock SJ, Simon R. Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial. Biometrics. 1975;31(1):103-15.
15. Kahan BC, Morris TP. Improper analysis of trials randomised using stratified blocks or minimisation. Stat Med. 2012;31(4):328-40.
16. Yang F, Zhang Y, Ressler SJ, Ittmann MM, Ayala GE, Dang TD, et al. FGFR1 is essential for prostate cancer progression and metastasis. Cancer Res. 2013;73(12):3716-24.
17. Zhang Y, Zhang J, Lin Y, Lan Y, Lin C, Xuan JW, et al. Role of epithelial cell fibroblast growth factor receptor substrate 2alpha in prostate development, regeneration and tumorigenesis. Development. 2008;135(4):775-84.
18. Li D, Wei X, Xie K, Chen K, Li J, Fang J. A novel decoy receptor fusion protein for FGF-2 potently inhibits tumour growth. Br J Cancer. 2014;111(1):68-77.
19. Ho TH, Jonasch E. Axitinib in the treatment of metastatic renal cell carcinoma. Future Oncol. 2011;7(11):1247-53.
20. Escudier B, Grunwald V, Ravaud A, Ou YC, Castellano D, Lin CC, et al. Phase II results of dovitinib (TKI258) in patients with metastatic renal cell cancer. Clin Cancer Res. 2014;20(11):3012-22.
21. Motzer RJ, Porta C, Vogelzang NJ, Sternberg CN, Szczylik C, Zolnierek J, et al. Dovitinib versus sorafenib for third-line targeted treatment of patients with metastatic renal cell carcinoma: an open-label, randomised phase 3 trial. Lancet Oncol. 2014;15(3):286-96.
22. Gerlinger M, Horswell S, Larkin J, Rowan AJ, Salm MP, Varela I, et al. Genomic architecture and evolution of clear cell renal cell carcinomas defined by multiregion sequencing. Nat Genet. 2014;46(3):225-33.
23. Gerlinger M, Rowan AJ, Horswell S, Larkin J, Endesfelder D, Gronroos E, et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med. 2012;366(10):883-92.
24. Cass JD, Varma S, Day AG, Sangrar W, Rajput AB, Raptis LH, et al. Automated quantitative analysis of p53, Cyclin D1, Ki67 and pERK expression in breast carcinoma does not differ from expert pathologist scoring and correlates with clinico-pathological characteristics. Cancers (Basel). 2012;4(3):725-42.
25. Zhang L, Bhasin M, Schor-Bardach R, Wang X, Collins MP, Panka D, et al. Resistance of renal cell carcinoma to sorafenib is mediated by potentially reversible gene expression. PLoS One. 2011;6(4), e19144.